Compass Therapeutics Outperforms Medical Stocks YTD with 17% Gain

Compass Therapeutics, Inc. (CMPX) has outperformed the Medical sector this year, with a 17% gain compared to the sector's 1.7% average. The stock has a Zacks Rank of #2 (Buy) and a 5.6% increase in full-year earnings estimates over the past 90 days. Ekso Bionics (EKSO) has also outperformed, with a 14.2% year-to-date gain and a 33.3% increase in consensus EPS estimates.